Septerna, Inc.

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Biotech IPOs staged a moderate recovery in 2024 but a muted end to the year showed how fragile the market remains for companies looking to launch. Full year data shows 26 companies debuted on US excha

The tally of biopharmaceutical companies that have gone public in the US in 2024 has now surpassed not only last year’s total but the total from 2022 now that Septerna Inc. has launched its IPO, gross

Stock market listings were back on the upswing last quarter, with the eight biotechs floating on Western exchanges raising a total of $1.1bn. In fact, there seems to have been a bit of a rush: three c